After a median follow-up of @ months -LSB- IQR @-@ -RSB- ) and @ ( @ % ) deaths ( @ in the docetaxel group , @ in the active symptom control group ) , median overall survival in the docetaxel group was @ months ( @ % CI @-@ @ ) versus @ months ( @-@ @ ) in the active symptom control group ( hazard ratio @ , @ % CI @-@ @ ; p = @ ) .